Clinical Trial Update: Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cadonilimab combined with chemotherapy as first- or second-line treatment for recurrent or metastatic triple-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Triple-negative Breast Cancer, Cadonilimab | Phase 2 | Status: RECRUITING